Middle East Pharmaceutical Industries (TADAWUL:4016) Full Year 2024 Results

Key Financial Results

• Revenue: ر.س394.0m (up 16% from FY 2023).
• Net income: ر.س79.8m (up 21% from FY 2023).
• Profit margin: 20% (in line with FY 2023).
• EPS: ر.س3.11.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Middle East Pharmaceutical Industries Earnings Insights

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Pharmaceuticals industry in Asia.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Middle East Pharmaceutical Industries' balance sheet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.